Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 30, Issue 4, Pages 782-788
Publisher
Springer Nature
Online
2015-11-19
DOI
10.1038/leu.2015.317
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
- (2013) C. D. DiNardo et al. BLOOD
- What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
- (2013) J.-A. Losman et al. GENES & DEVELOPMENT
- High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial
- (2013) Markus Schaich et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
- (2013) Maxime Janin et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
- (2013) J.-H. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
- (2013) J.-A. Losman et al. SCIENCE
- The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
- (2013) Dinesh Rakheja et al. Frontiers in Oncology
- Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate
- (2012) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
- (2012) A. T. Fathi et al. BLOOD
- The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
- (2011) C. L. Green et al. BLOOD
- Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry
- (2011) Felix Sahm et al. BRAIN PATHOLOGY
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
- (2010) F. Thol et al. BLOOD
- Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
- (2010) W. C. Chou et al. BLOOD
- IDH1 and IDH2: Not Your Typical Oncogenes
- (2010) Zachary J. Reitman et al. CANCER CELL
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations
- (2010) Leopold Sellner et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
- (2010) F. Thol et al. HAEMATOLOGICA
- Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
- (2010) Nicolas Boissel et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
- (2010) Katharina Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
- (2010) W-C Chou et al. LEUKEMIA
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
- (2008) I H I M Hollink et al. LEUKEMIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started